Skip to main content

8-K

Scynexis Inc (SCYX)

8-K 2024-06-20 For: 2024-06-19
View Original
Added on April 09, 2026

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 19, 2024

SCYNEXIS, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware 001-36365 56-2181648
(State or Other Jurisdiction<br>of Incorporation) (Commission File Number) (IRS Employer<br>Identification No.)
1 Evertrust Plaza<br><br>13th Floor
Jersey City, New Jersey 07302-6548
(Address of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, Including Area Code: 201 884-5485
---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading<br>Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share SCYX The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 19, 2024, SCYNEXIS, Inc. held its 2024 Annual Meeting of Stockholders. The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final tally of the number of votes cast: (a) for or withheld with respect to the election of directors; (b) for, against or abstain for the ratification of the appointment of Deloitte & Touche LLP as SCYNEXIS’s independent registered public accounting firm for the fiscal year ending December 31, 2024; (c) for, against or abstain for the advisory approval of the executive compensation as disclosed in SCYNEXIS’s proxy statement, filed with the Securities and Exchange Commission on April 25, 2024 (the “Proxy Statement”); and (d) for, against or abstain for the approval of the SCYNEXIS, Inc. 2024 Equity Incentive Plan. Broker non-votes are also reported. A more complete description of each matter is set forth in the Proxy Statement.

Proposal 1: Each of the seven directors proposed by SCYNEXIS for re-election was elected to serve until SCYNEXIS’s 2025 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified. The tabulation of votes on this matter was as follows:
For Withheld Broker<br>Non-Votes
David Angulo, M.D. 14,952,407 508,995 10,498,371
Armando Anido 14,119,574 1,341,828 10,498,371
Steven C. Gilman, Ph.D. 14,027,862 1,433,540 10,498,371
Ann F. Hanham, Ph.D. 14,223,819 1,237,583 10,498,371
David Hastings 14,910,344 551,058 10,498,371
Guy Macdonald 14,830,674 630,728 10,498,371
Philippe Tinmouth 14,790,479 670,923 10,498,371
Proposal 2: The appointment of Deloitte & Touche LLP as SCYNEXIS’s independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. The tabulation of votes on this matter was as follows:
--- ---
For Against Abstain Broker<br>Non-Votes
--- --- --- ---
25,192,381 698,103 69,289
Proposal 3: Advisory approval of the compensation of SCYNEXIS's named executive officers as disclosed in the Proxy Statement, was approved. The tabulation of votes on this matter was as follows:
--- ---
For Against Abstain Broker<br>Non-Votes
--- --- --- ---
13,476,050 1,616,310 369,042 10,498,371
Proposal 4: The SCYNEXIS, Inc. 2024 Equity Incentive Plan was approved. The tabulation of votes on this matter was as follows:
--- ---
For Against Abstain Broker<br>Non-Votes
--- --- --- ---
12,891,296 2,221,209 348,897 10,498,371

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCYNEXIS, Inc.
Date: June 19, 2024 By: /s/ David Angulo, M.D.
Name:<br><br>Its: David Angulo, M.D.<br>Chief Executive Officer